TSMHT
ACAD icon

Thurston Springer Miller Herd & Titak’s Acadia Pharmaceuticals ACAD Stock Holding History

Thurston Springer Miller Herd & Titak’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-53
Closed -$1.14K – 543
2025
Q2 		$1.14K Buy
+53
New +$985 ﹤0.01% 1487
2024
Q2 		– Sell
-53
Closed -$979 – 1527
2024
Q1 		$979 Buy
+53
New +$1.31K ﹤0.01% 152

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Thurston Springer Miller Herd & Titak's ACAD Position: Q3 2025 in Review

Thurston Springer Miller Herd & Titak sold out of Acadia Pharmaceuticals (ACAD) in Q3 2025, closing a stake of 53 shares — an estimated $1.14K sold.

Thurston Springer Miller Herd & Titak first reported a position in ACAD in Q1 2024 and held it in 2 quarters. The position peaked at $1.14K in Q2 2025. 334 funds tracked by Wall St. Rank hold ACAD as of Q3 2025.

  • Thurston Springer Miller Herd & Titak reported no remaining Acadia Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Thurston Springer Miller Herd & Titak sold 53 Acadia Pharmaceuticals shares in Q3 2025, an estimated $1.14K.
  • Thurston Springer Miller Herd & Titak first reported a position in Acadia Pharmaceuticals in Q1 2024 and held it in 2 quarters.
  • Thurston Springer Miller Herd & Titak's Acadia Pharmaceuticals position peaked at $1.14K in Q2 2025.
  • 334 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2025.

Based on Thurston Springer Miller Herd & Titak's 13F filing for Q3 2025, filed 7 Oct 2025.